Highest-materiality recent filing
TherapeuticsMD Q1 2026 net income $103K, license revenue up 84% YoY
Net income from continuing operations of $103K vs net loss of $636K in Q1 2025.
TherapeuticsMD reports 2025 full-year net loss of $0.7M, license revenue up 71.6% to $3.0M
Net loss from continuing operations narrowed to $0.7M ($0.06 per share) from $2.3M in 2024.
TherapeuticsMD appoints CRI as new auditor; prior reports included going concern emphasis
Audit Committee approved CRI as independent auditor effective Jan 15, 2026; BPB dismissed.
TherapeuticsMD shareholders approve all proposals including share authorization increase to 640M
Four director nominees elected: Thompson, Collins, Naughton, Roberts; each received >5.1M for votes.
TherapeuticsMD posts Q3 net income of $50K vs year-ago loss; license revenue up 43%
Net income from continuing operations was $50K ($0.00 per share) vs net loss of $567K ($0.05) in Q3 2024.
TherapeuticsMD Q2 net income $545K vs loss last year; license revenue up to $1.0M
Net income from continuing operations $545K ($0.05/share) vs net loss of -$1.05M (-$0.09) in Q2 2024.
TherapeuticsMD Q1 net loss narrows to $636K; license revenue up 26%
Net loss from continuing ops $(636)K ($0.06/sh) vs $(809)K ($0.07/sh) in Q1 2024.
TherapeuticsMD files lawsuit against Mayne Pharma for breach of contract over 2022 agreements
Filed April 8, 2025 in U.S. District Court for Delaware (Case No. not assigned).
TherapeuticsMD reports FY2024 net loss narrowed to $2.3M; license revenue up 35%
Net loss from continuing operations $(2.3)M, or $(0.20)/share, improved from $(7.7)M loss in 2023.
All four board nominees elected: Thompson 4.60M for, Collins 4.73M, Naughton 4.64M, Roberts 4.63M; broker non-votes 1.97M each.
TherapeuticsMD narrows Q3 net loss to $567K; license revenue rises to $547K
Net loss from continuing operations of $567K ($0.05 per share) vs. $1.4M loss ($0.13) in Q3 2023.
TherapeuticsMD sets 2024 annual meeting for Dec 5; proxy deadlines Sep 30
2024 Annual Meeting scheduled for December 5, 2024; record date October 17, 2024.
TherapeuticsMD Q2 net loss narrows to $1.05M; evaluating strategic alternatives
Net loss from continuing operations $1.05M ($0.09/sh) vs $2.4M ($0.24/sh) in Q2 2023.
TherapeuticsMD Q1 net loss narrows to $0.8M; strategic alternatives review ongoing
Net loss from continuing operations of $0.8M ($0.07/share) vs. $2.3M ($0.24/share) in Q1 2023.
TherapeuticsMD full-year 2023 net loss $7.7M, cash $4.3M; strategic review ongoing
Net loss from continuing operations $(7.7)M ($(0.74) per share) vs $1.1M income ($0.12) in 2022.
TherapeuticsMD reports Q3 net loss $1.4M; evaluates strategic alternatives
Net loss from continuing ops $1.4M ($0.13/share) vs $14.6M ($1.58) in Q3 2022.
Entered Master Services Agreement with JZ Advisory Group for $10,000/month plus 7,500 restricted stock units for Joseph Ziegler as Principal Financial Officer
TherapeuticsMD Q2 net loss narrows to $2.4M as royalty transition continues
Net loss from continuing ops of $2.4M ($0.24 per share) vs $14.9M ($1.70) in Q2 2022.
TherapeuticsMD dismisses Grant Thornton, engages BPB; prior reports had going concern note
Grant Thornton dismissed as independent auditor on July 7, 2023; Berkowitz Pollack Brant appointed.
TherapeuticsMD issues 312,525 shares to Rubric Capital for $1.15M; amends bylaws
Issued 312,525 shares at $3.6797/share to Rubric Capital Management on June 29, 2023, gross proceeds $1,149,998.
TherapeuticsMD stockholders approve charter amendment and private placement at 2023 annual meeting
Elected all four director nominees (Thompson, Collins, Naughton, Roberts) with over 4 million 'for' votes each.
TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share
Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.
TherapeuticsMD enters $5M private placement with Rubric Capital
Agreement to sell up to 5M shares at volume-weighted average price, aggregate up to $5M.
TherapeuticsMD sets combined 2022/2023 annual meeting for June 19, 2023
Annual meeting set for June 19, 2023; record date April 20, 2023 (past).
TherapeuticsMD posts $1.1M net income from continuing ops in FY2022 vs loss of $79.3M in 2021
License revenue surged to $70.0M from $2.6M, driven by $140M upfront from Mayne Pharma transaction.
TherapeuticsMD amends CEO Walker's employment; enters consulting agreement with former CFO Donegan
CEO Walker's base salary increased to $500k after Apr 15, 2023; receives $20,909 lump-sum bonus and 70,000 RSUs.
TherapeuticsMD terminates employment agreement of CFO Michael Donegan; remains as consulting CFO
CFO Michael Donegan's employment agreement terminated without 'Good Cause' effective Dec 30, 2022.
Received Nasdaq deficiency letter on Jan 6, 2023 for failing to hold 2022 annual meeting within 12 months of FYE Dec 31, 2021.
TherapeuticsMD closes Mayne Pharma license deal, appoints new CEO, reports pro forma loss
On Dec 30, 2022, terminated co-CEOs Brian Bernick and Mark Glickman; Glickman eligible for $100k consulting fee plus performance bonuses.
Total upfront cash of ~$153.1M ($140M license/sale + $13.1M for working capital and prepaid royalties).
TherapeuticsMD licenses products to Mayne Pharma for ~$153.1M upfront plus royalties and milestones
Upfront cash payment of $140.0M plus ~$13.1M for net working capital at closing.
TherapeuticsMD extends debt maturity to Dec 31, 2022; pays $4.2M accrued interest and $750K fee
Amendment No. 17 extends Financing Agreement maturity to Dec 31, 2022, contingent on certain milestones.
TherapeuticsMD Q3 revenue $20.9M, net loss $29.0M; cash drops to $27.1M
Net revenue $20.9M, down 18% YoY; net loss $29.0M ($3.13/sh) vs $47.4M loss YoY.
TherapeuticsMD raises $7M from Rubric Capital; extends debt maturity to Nov 30
Issued 7,000 shares of Series A Preferred Stock to Rubric Capital Management for $7M gross proceeds.
Issued 7,000 Series A Preferred shares to Rubric Capital Management for $7M gross proceeds; proceeds for working capital.
TherapeuticsMD CEO departs; co-founder & CBO named interim co-CEOs; strategic review ongoing
CEO Hugh O'Dowd departed Sept 6, 2022; termination without 'Good Cause' triggers severance.
TherapeuticsMD appoints Rubric Capital partner Justin Roberts to board of directors
Justin Roberts, Partner at Rubric Capital Management, appointed to fill newly created Board seat effective Aug. 23, 2022.
TherapeuticsMD Q2 net income $112.3M; revenue $28.6M (+24% YoY); ANNOVERA sales double
Net revenue $28.6M, up 24% YoY; net income $112.3M ($12.83 basic EPS) vs net loss $42.7M in Q2 2021.
TherapeuticsMD raises $15M from Rubric, extends debt maturity to Sept 2022
Issued 15,000 Series A Preferred ($1,000 stated value) and 565,000 common shares to Rubric for $15M gross proceeds.
TherapeuticsMD extends loan maturity to July 29, 2022; evaluating Chapter 11 protection
Maturity date of Financing Agreement amended to July 29, 2022, a one-day extension from the amendment date.
TherapeuticsMD extends loan maturity by one day, evaluating Chapter 11 filing
Extended maturity of Financing Agreement from July 27 to July 28, 2022.
TherapeuticsMD extends loan maturity to July 27, appoints CRO, explores Chapter 11
Amendment No. 13 extends Financing Agreement maturity to July 27, 2022.
TherapeuticsMD terminates Merger Agreement; debt maturity extended to July 24; evaluating Chapter 11
Tender offer at $10/share expired July 12 without acquiring required majority; Merger Agreement terminated July 13.
Bylaw amendment adopted May 27, 2022, makes Nevada control share statutes inapplicable to the merger agreement with Athene Parent and Merger Sub.
TherapeuticsMD signs merger agreement with Athene Parent for cash tender offer and merger
Merger Agreement dated May 27, 2022 with Athene Parent, Inc. and Athene Merger Sub, Inc.
TherapeuticsMD to be acquired by EW Healthcare Partners for $10.00/share in all-cash deal
Offer price of $10.00 per share represents 367.3% premium over May 27 closing price.
FDA approves TherapeuticsMD's ANNOVERA sNDA, boosting supply by ~7,000 rings
FDA approved sNDA for ANNOVERA with revised in vitro release testing specification to allow normal manufacturing variability.
TherapeuticsMD Q1 net loss $49M on flat revenue; completes $150M vitaCare sale
Total net product revenue $19.3M, down slightly from $19.6M Q1 2021.
TherapeuticsMD effects 1-for-50 reverse stock split; authorized shares cut to 12M
Reverse split effective May 6, 2022; every 50 shares become 1 share.
TherapeuticsMD announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance
Board approves 1-for-50 reverse stock split to cure Nasdaq minimum bid price non-compliance.
On August 17, 2023, Mr. Michael C. Donegan, the Principal Financial and Accounting Officer of the Company, notified the Company of his decision to resign from such positions, effective as of August 17, 2023.
Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the effective date of Mr. Donegan’s resignation.
terminated that certain amended and restated employment agreement, dated November 24, 2020, by and between the Company and Mr. Michael Donegan, the Company’s former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.
Effective February 21, 2023, the Company entered into a General Consulting and Services Agreement (the “Consulting Agreement”) with MCD Consulting and Management Services, LLC (“MCD”), the manager of which is Mr. Donegan, the Company’s Principal Financial Officer (“PFO”) and Principal Accounting Officer (“PAO”) and former Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance.
Mr. Donegan is continuing to serve as the Company’s Principal Financial Officer and Principal Accounting Officer in a consulting capacity.
On January 4, 2023, the Board appointed Mr. Marlan Walker, the Company’s General Counsel, as the Company’s Chief Executive Officer and Principal Executive Officer.
On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.
On December 30, 2022 (the “Closing Date”), the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers.
On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.
On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.
On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.
On December 30, 2022, each of Mr. Paul M. Bisaro, Ms. Karen L. Ling, Mr. Jules A. Musing and Mr. Angus C. Russell resigned from the board of directors (the “Board”) of the Company, and any committees thereof, effective upon the closing of the Transaction.
Max materiality 1.00 · Median 0.60 · Most common event earnings